- Home
- MGRX vs BCDA Comparison
MGRX vs BCDA Comparison
Compare MGRX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- BCDA
- Stock Information
- Founded
- MGRX 2021
- BCDA N/A
- Country
- MGRX United States
- BCDA United States
- Employees
- MGRX N/A
- BCDA N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- BCDA Health Care
- Exchange
- MGRX Nasdaq
- BCDA Nasdaq
- Market Cap
- MGRX 8.1M
- BCDA 9.4M
- IPO Year
- MGRX 2023
- BCDA N/A
- Fundamental
- Price
- MGRX $2.10
- BCDA $1.82
- Analyst Decision
- MGRX
- BCDA Strong Buy
- Analyst Count
- MGRX 0
- BCDA 1
- Target Price
- MGRX N/A
- BCDA $25.00
- AVG Volume (30 Days)
- MGRX 223.6K
- BCDA 92.0K
- Earning Date
- MGRX 05-14-2025
- BCDA 05-13-2025
- Dividend Yield
- MGRX N/A
- BCDA N/A
- EPS Growth
- MGRX N/A
- BCDA N/A
- EPS
- MGRX N/A
- BCDA N/A
- Revenue
- MGRX $615,873.00
- BCDA $58,000.00
- Revenue This Year
- MGRX N/A
- BCDA N/A
- Revenue Next Year
- MGRX N/A
- BCDA N/A
- P/E Ratio
- MGRX N/A
- BCDA N/A
- Revenue Growth
- MGRX N/A
- BCDA N/A
- 52 Week Low
- MGRX $1.49
- BCDA $1.63
- 52 Week High
- MGRX $16.80
- BCDA $6.15
- Technical
- Relative Strength Index (RSI)
- MGRX 43.32
- BCDA 36.67
- Support Level
- MGRX $1.63
- BCDA $1.73
- Resistance Level
- MGRX $2.85
- BCDA $1.93
- Average True Range (ATR)
- MGRX 0.37
- BCDA 0.14
- MACD
- MGRX 0.11
- BCDA -0.02
- Stochastic Oscillator
- MGRX 44.24
- BCDA 20.24
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).